The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CYDY | +76.91% | -94.93% | -44.9% | -59% |
| S&P | +16.72% | +84.29% | +13% | +459% |
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.
Failure is not an option for this small-cap biotech developing a COVID-19 treatment.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$5.00K | -25.0% |
| Market Cap | $414.44M | 195.9% |
| Market Cap / Employee | $31.88M | 0.0% |
| Employees | 13 | 44.4% |
| Net Income | -$22,607.00K | -374.1% |
| EBITDA | -$5,096.00K | -37.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.98M | -76.6% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $27.27M | -4.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -229.87% | -146.3% |
| Return On Invested Capital | 239.80% | 413.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,350.00K | -21.3% |
| Operating Free Cash Flow | -$4,350.00K | -21.3% |
| Metric | Q2 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 148.70 | - | |||
| Price to Book | -4.20 | -4.53 | -3.90 | -4.15 | 152.24% |
| Price to Tangible Book Value | -4.20 | -4.53 | -3.90 | -4.15 | 152.27% |
| Enterprise Value to EBITDA | -97.10 | -92.74 | -79.66 | -85.60 | 114.72% |
| Total Debt | $27.32M | $27.34M | $27.31M | $27.27M | -5.12% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
